Baiyunshan Q1 Revenue Rises as Profit Margins Narrow and Cash Outflows Ease

Guangzhou Baiyunshan Pharmaceutical Holdings reported a 3.58% year-on-year increase in Q1 2026 revenue, totaling RMB23.28 billion. However, net profit attributable to shareholders fell by 2.06% to RMB1.78 billion, with total profit down 1.04%. Despite this, underlying profitability improved, with net profit after non-recurring items rising 1.72% and operating cash outflows narrowing by 43.10%. The company's earnings per share decreased to RMB1.097, indicating a challenging profit environment, while total assets and shareholders’ equity grew by 6.21% and 4.69%, respectively. The market cap stands at HK$39.99B, with a YTD price performance of -5.19%.